171 related articles for article (PubMed ID: 30719557)
1. Health-Related Quality of Life Associated with Barrett's Esophagus and Cancer.
Bulamu NB; Chen G; Ratcliffe J; Schloite A; Bright T; Watson DI
World J Surg; 2019 Jun; 43(6):1554-1562. PubMed ID: 30719557
[TBL] [Abstract][Full Text] [Related]
2. Responsiveness and convergent validity of QLU-C10D and EQ-5D-3L in assessing short-term quality of life following esophagectomy.
Bulamu NB; Vissapragada R; Chen G; Ratcliffe J; Mudge LA; Smithers BM; Isenring EA; Smith L; Jamieson GG; Watson DI;
Health Qual Life Outcomes; 2021 Oct; 19(1):233. PubMed ID: 34600554
[TBL] [Abstract][Full Text] [Related]
3. Quality of life and fear of cancer recurrence after endoscopic treatment for early Barrett's neoplasia: a prospective study.
Rosmolen WD; Nieuwkerk PT; Pouw RE; van Berge Henegouwen MI; Bergman JJ; Sprangers MA
Dis Esophagus; 2017 Feb; 30(3):1-9. PubMed ID: 27766707
[TBL] [Abstract][Full Text] [Related]
4. Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients.
Pan CW; He JY; Zhu YB; Zhao CH; Luo N; Wang P
Eur J Health Econ; 2023 Aug; 24(6):885-893. PubMed ID: 36083356
[TBL] [Abstract][Full Text] [Related]
5. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
Lamu AN; Olsen JA
Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
[TBL] [Abstract][Full Text] [Related]
6. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
Yousefi M; Nahvijou A; Sari AA; Ameri H
Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
[TBL] [Abstract][Full Text] [Related]
7. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
8. Estimation of Health-Related Utilities for
Soare IA; Leeuwenkamp O; Longworth L
Pharmacoecon Open; 2021 Dec; 5(4):715-725. PubMed ID: 34260017
[TBL] [Abstract][Full Text] [Related]
9. Perceptions of risk and therapy among patients with Barrett's esophagus: a patient survey study.
Stier MW; Lodhia N; Jacobs J; Nozicka D; Kavitt R; Siddiqui U; Waxman I; Konda VJ
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29036278
[TBL] [Abstract][Full Text] [Related]
10. Which approach is better in eliciting health state utilities from breast cancer patients? Evidence from mainland China.
Li S; Wang M; Liu L; Chen G
Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12965. PubMed ID: 30499193
[TBL] [Abstract][Full Text] [Related]
11. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.
Huang D; Zeng D; Tang Y; Jiang L; Yang Q
Qual Life Res; 2024 Feb; 33(2):491-505. PubMed ID: 37938402
[TBL] [Abstract][Full Text] [Related]
12. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
13. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
[TBL] [Abstract][Full Text] [Related]
14. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs.
Pilz MJ; Seyringer S; Al-Naesan I; King MT; Bottomley A; Norman R; Schlosser L; Hell T; Gamper EM;
Pharmacoecon Open; 2024 May; ():. PubMed ID: 38696019
[TBL] [Abstract][Full Text] [Related]
15. Quality of life in patients with various Barrett's esophagus associated health states.
Hur C; Wittenberg E; Nishioka NS; Gazelle GS
Health Qual Life Outcomes; 2006 Aug; 4():45. PubMed ID: 16884539
[TBL] [Abstract][Full Text] [Related]
16. The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L.
Gamper EM; Cottone F; Sommer K; Norman R; King M; Breccia M; Caocci G; Patriarca A; Palumbo GA; Stauder R; Niscola P; Platzbecker U; Caers J; Vignetti M; Efficace F
J Clin Epidemiol; 2021 Sep; 137():31-44. PubMed ID: 33753228
[TBL] [Abstract][Full Text] [Related]
17. Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D.
Jansen F; Verdonck-de Leeuw IM; Gamper E; Norman R; Holzner B; King M; Kemmler G;
Qual Life Res; 2021 Jul; 30(7):2009-2019. PubMed ID: 33512653
[TBL] [Abstract][Full Text] [Related]
18. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).
Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N
Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850
[TBL] [Abstract][Full Text] [Related]
20. Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.
Kim H; Cook G; Goodall S; Liew D
Pharmacoecon Open; 2021 Sep; 5(3):459-467. PubMed ID: 33891268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
